(December 4, 2015) According to the results of a phase III trial of over 1,000 women, women with advanced ovarian cancer gained significant delays in the progression of their disease when they were treated with the drug nintedanib plus carboplatin/paclitaxel, compared with women treated with carboplatin/paclitaxel alone. The results of the study were published in the British journal The Lancet.
The efficacy of the drug seemed to be especially powerful in patients with a small amount of cancer remaining after surgery. The study authors comment that “pending the overall survival results, further studies are needed to prospectively assess the clinical value of nintedanib in patients with advanced ovarian cancer and especially in cohorts with lower tumor burden.”
Click here to read a story about this research; click here to read the abstract.
